Sequent - Potential Double Bottom
A stock that has faced a world of headwinds and is slowly but surely setting up for a bright future in animal pharma.
There is a RSI +ive divergence and also the stock has bounced off what could be a double bottom. This more more of a long term investors pick though and not for a quick trade.
Long at current market price and a deep deep stoploss below 95. (Carlyle got the co at 98 so i assume they would become active around those prices again).
This co might not generate quick returns and this quarters result might not be the best either so 50% at current price and 50% post results might be a smart play too (Results 25th May).
There is a RSI +ive divergence and also the stock has bounced off what could be a double bottom. This more more of a long term investors pick though and not for a quick trade.
Long at current market price and a deep deep stoploss below 95. (Carlyle got the co at 98 so i assume they would become active around those prices again).
This co might not generate quick returns and this quarters result might not be the best either so 50% at current price and 50% post results might be a smart play too (Results 25th May).
Komen:
Carlyle Deal was at Rs86. The SL would still be the same though.